Literature DB >> 16218878

Degradation of the sodium taurocholate cotransporting polypeptide (NTCP) by the ubiquitin-proteasome system.

Thomas Kühlkamp1, Verena Keitel, Angelika Helmer, Dieter Häussinger, Ralf Kubitz.   

Abstract

The sodium taurocholate cotransporting polypeptide (Ntcp, Slc10a1) is the major uptake system for bile acids into liver cells. This study investigated the degradation of rat Ntcp and human NTCP by the ubiquitin-proteasome system (UPS). In stably transfected HepG2 cells, rat Ntcp was complex-glycosylated and localized at the plasma membrane. Inhibition of proteasomes by MG-132 or lactacystin led to the accumulation of intracellular Ntcp, a process dependent on de novo protein synthesis. Intracellular Ntcp was core-glycosylated, indicating an endoplasmic reticulum (ER) origin. Core-glycosylated Ntcp was found in cytosolic, detergent-insoluble deposits with characteristics of aggresomes: they co-localized with ubiquitin at the microtubule organization center and Ntcp from these deposits was polyubiquitinated. Transient transfections of Ntcp/NTCP induced intracellular deposits that co-localized with ubiquitin, even in the absence of proteasome inhibitors. Similarly, in livers of patients with progressive familial intrahepatic cholestasis, NTCP could be detected co-localized with ubiquitin in hepatocytes. We conclude that maturing Ntcp/NTCP is degraded by the ubiquitin-proteasome system at the level of ER-associated degradation (ERAD). An imbalance in the synthesis and degradation of NTCP at the level of the ER or alterations in the ERAD machinery might be the cause of intracellular NTCP deposits in transient transfections and in cholestatic livers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16218878     DOI: 10.1515/BC.2005.122

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  12 in total

1.  Cysteine 96 of Ntcp is responsible for NO-mediated inhibition of taurocholate uptake.

Authors:  Umadevi Ramasamy; M Sawkat Anwer; Christopher M Schonhoff
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-07-25       Impact factor: 4.052

2.  Nitric oxide-mediated inhibition of taurocholate uptake involves S-nitrosylation of NTCP.

Authors:  Christopher M Schonhoff; Umadevi Ramasamy; M Sawkat Anwer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-11-25       Impact factor: 4.052

3.  Genetic variation in the mouse model of Niemann Pick C1 affects female, as well as male, adiposity, and hepatic bile transporters but has indeterminate effects on caveolae.

Authors:  David A Jelinek; Bita Maghsoodi; Ivan A Borbon; Rhiannon N Hardwick; Nathan J Cherrington; Robert P Erickson
Journal:  Gene       Date:  2011-10-14       Impact factor: 3.688

Review 4.  Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology.

Authors:  Claudia D Fuchs; Michael Trauner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-02-14       Impact factor: 73.082

Review 5.  Bile acid transporters in health and disease.

Authors:  A Kosters; S J Karpen
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

Review 6.  Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters.

Authors:  M Sawkat Anwer; Bruno Stieger
Journal:  Pflugers Arch       Date:  2013-10-03       Impact factor: 3.657

7.  Effects of perinatal PBDE exposure on hepatic phase I, phase II, phase III, and deiodinase 1 gene expression involved in thyroid hormone metabolism in male rat pups.

Authors:  David T Szabo; Vicki M Richardson; David G Ross; Janet J Diliberto; Prasada R S Kodavanti; Linda S Birnbaum
Journal:  Toxicol Sci       Date:  2008-10-31       Impact factor: 4.849

Review 8.  Xenobiotic, bile acid, and cholesterol transporters: function and regulation.

Authors:  Curtis D Klaassen; Lauren M Aleksunes
Journal:  Pharmacol Rev       Date:  2010-01-26       Impact factor: 25.468

Review 9.  Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions.

Authors:  Khondoker Alam; Alexandra Crowe; Xueying Wang; Pengyue Zhang; Kai Ding; Lang Li; Wei Yue
Journal:  Int J Mol Sci       Date:  2018-03-14       Impact factor: 5.923

10.  Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner.

Authors:  Khondoker Alam; Taleah Farasyn; Alexandra Crowe; Kai Ding; Wei Yue
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.